ImmunityBio, Inc.
Develops immunotherapies and vaccines to combat cancer and infectious diseases.
IBRX | US
Overview
Corporate Details
- ISIN(s):
- US45256X1037
- LEI:
- Country:
- United States of America
- Address:
- 3530 JOHN HOPKINS COURT, 92121 SAN DIEGO
- Website:
- https://immunitybio.com/
- Sector:
- Manufacturing
Description
ImmunityBio, Inc. is a commercial-stage biotechnology company developing next-generation immunotherapies and vaccines designed to strengthen a patient's own immune system. The company's approach focuses on orchestrating both the innate (natural killer cells) and adaptive (T cells) immune systems to combat cancer and infectious diseases. Its key platforms include the IL-15 superagonist Anktiva® (N-803), engineered natural killer (NK) cell therapies, and adenovirus-vectored vaccines. These therapies are being investigated and applied across a range of difficult-to-treat cancers, such as bladder, lung, and pancreatic cancers, as well as infectious diseases like HIV. The company's goal is to create durable, complete responses by treating the host's immune system rather than just the disease.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all ImmunityBio, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for ImmunityBio, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for ImmunityBio, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
